Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

NCT06629363 | Not Yet Recruiting

• 1 other identifier: 2025-A01738-41
• Study Type: observational
• Target: 1,000
• Locations: 0 countries
• Sites: N/A

Brief Summary

The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

Conditions

Malignant Hypertension

Keywords

Malignant hypertension; severe hypertension; hypertensive emergency; target organ damage; pathophysiology; biomarkers

Outcome Measures

Primary Outcomes (1)

• Decipher the mechanisms responsible for the transition from severe to malignant hypertension

  Compare the multiomic signature of patients admitted for malignant hypertension, between MHT acute crisis (admission) and resolution (6 month later). Transcriptomic, proteomic and metabolomic evolution between these 2 time points and focus on genetic background in relevant system, like angiogenic, vasoactif system, complement system and inflammasome will be described.

  At inclusion and 6 month

Secondary Outcomes (2)

• Understand the determinants of the heterogeneity in target organs damages (TOD) during MHT crisis

  At inclusion

• Focus on the role of complement system in MHT crisis

  At inclusion and 6 month

Interventions

biobank OTHER

The following samples will be collected : * Serum samples and plasma sample: inclusion visit and follow up visit * Urines samples : inclusion visit and follow up visit * blood DNA: inclusion visit * Blood RNA: inclusion visit and follow up visit

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with malignant hypertension

You may qualify if:

• patients included in the HAMA cohort with the following critera :
• Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy)
• Severe hypertension associated with acute target organ damage due to high blood pressure

You may not qualify if:

• Refusal to participate to the substudy " HAMA bank "
• patient on chronic dialysis

Sponsors & Collaborators

• Centre Hospitalier de PAU: lead

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample for DNA

MeSH Terms

Conditions

Hypertension, Malignant; Hypertension; Hypertensive Crisis

Interventions

Biological Specimen Banks

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Health Facilities; Health Care Facilities Workforce and Services

Study Officials

• Romain BOULESTREAU

  University Hospital, Bordeaux

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Alice SERIS

CONTACT

0559726997; alice.seris@ch-pau.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2024
• First Posted: October 8, 2024
• Study Start: August 1, 2025
• Primary Completion (Estimated): April 1, 2036
• Study Completion (Estimated): April 1, 2036
• Last Updated: July 30, 2025

Record last verified: 2025-07